Sovaldi, which won U.S. approval in December, has been a lightning rod for a fierce debate over prescription drug prices.
Its $84,000 cost for a 12-week course of treatment, about $1,000 per pill, has caused concerns that high demand will place a huge burden on government-run health plans and private health insurers.
The company posted second-quarter earnings, excluding items, of $2.36 per share up from 50 cents a share in the year-earlier period. Revenue increased to $6.53 billion from $2.77 billion a year ago.
Analysts had expected the company to report earnings of $1.79 a share on $5.86 billion in revenue, according to a consensus estimate from Thomson Reuters.
Watch: What's coming in Biotech?
Earlier on Wednesday, Gilead's Zydelig drug, which will compete with Pharmacyclics' drug Imbruvica, received Food and Drug Administration approval to treat three types of blood cancer.
It was also approved under a so-called accelerated approval program for relapsed follicular B-cell non-Hodgkin lymphoma (NHL) and relapsed small lymphocytic lymphoma, when patients have received at least two prior therapies.
As of Tuesday's close, Gilead shares had gained more than 33 percent over the last 12 months.
Reuters contributed to this story.